Current Report Filing (8-k)
May 15 2020 - 9:15AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): May 14, 2020
CO-DIAGNOSTICS,
INC.
|
(Exact
name of small business issuer as specified in its charter)
|
Utah
|
|
1-38148
|
|
46-2609363
|
(State
or other jurisdiction
of
incorporation or organization)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
2401
S. Foothill Drive, Suite D, Salt Lake City, Utah 84109
(Address
of principal executive offices)
(801)
438-1036
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
CODX
|
|
NASDAQ
Capital Market
|
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 2.02. Results of Operations and Financial Condition.
On
May 14, 2020, Co-Diagnostics, Inc. (the “Company”) issued a press release reporting the financial results of the Company
for the three months ended March 31, 2020. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated
herein by this reference.
Also,
on May 14, 2020, the Company held a conference call. A transcript of the call is attached as Exhibit 99.2 to this Current Report
on Form 8-K.
Item 7.01. Regulation FD Disclosure.
As
noted above, the Company held a conference call on May 14, 2020, to discuss the Company’s operating results for the three
months ended March 31, 2020. The telephone bridge was not sufficient to allow the call to take place and a transcript of the call
is attached as Exhibit 99.2 to this Current Report on Form 8-K.
A
copy of the press release, which contains additional information regarding how to access the conference call and how to listen
to a recorded playback of the call, is attached as Exhibit 99.1 to this Current Report on Form 8-K. A transcript of the call is
attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
*
* * *
The
information discussed under Item 2.02 and Item 7.01 above, including Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing by the
Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
|
CO-DIAGNOSTICS,
INC.
|
|
|
|
|
By:
|
/s/
Dwight H. Egan
|
|
Name:
|
Dwight
H. Egan
|
|
Title:
|
Chief
Executive Officer
|
Date:
May 15, 2020
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024